Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a report date of February 17, 2022. The filing discloses the grant of conditional share awards under the 2017 Performance Share Plan to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The awards are subject to a three-year performance period from January 1, 2022, to December 31, 2024.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics for the company. The only financial data provided relates to the valuation of executive compensation awards granted on February 15, 2022:
- Share Price (Ordinary Shares): GBP 15.712
- Share Price (ADS): USD 42.87
- Total Awards Granted: Approximately 1,960,615 Ordinary Shares and 52,484 ADSs were granted to 14 individuals (including one PCA).
Material Changes
The filing details the introduction of new performance measures for the 2022 awards compared to prior years:
- New ESG Measure: A 10% weighting has been added for "ESG: Environment," focusing on Nature Net Positive and Climate Net Zero goals by 2030.
- Threshold Adjustments: The threshold for vesting on Total Sales and Profit measures is set at 99% of target (up from previous standards), with a maximum vesting of 100% at 105% of target.
- Exclusions: Current employees moving to the new consumer healthcare business were excluded from these awards and will receive separate awards aligned with the new entity's strategy.
- TSR: Compared against a peer group of 9 other global pharmaceutical companies. Vesting ranges from 0% (6th or below) to 100% (1st-3rd).
- Pipeline Progress: Based on pivotal trial starts and major regulatory approvals. Specific targets are commercially sensitive and not disclosed.
- Holding Period: Executive Directors are subject to an additional two-year holding period post-vesting (5 years total), during which shares are forfeitable only for cause.
- Verify the specific commercial targets for Total Sales, Profit, and Pipeline Progress once disclosed at the end of the 2024 performance period.
- Monitor the composition of the TSR comparator group to ensure it remains consistent with the 10 companies listed (AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi, GSK).
- Track progress on the six ESG KPIs (three Climate, three Nature) required to achieve 75% or 100% vesting on the environmental measure.
- Confirm the separation of consumer healthcare employees and their subsequent compensation alignment with the new business entity.
Guidance, Outlook, and Risks
Performance Measures and Vesting: The awards vest based on five measures: Relative Total Shareholder Return (TSR) (30%), GSK Total Sales (20%), GSK Profit (20%), Pipeline Progress (20%), and ESG Environment (10%).
Risks and Contingencies: If performance targets are not met, the conditional awards will lapse. Dividends accrue on the awards but only vest if the underlying shares vest. Specific targets for Sales, Profit, and Pipeline Progress are not disclosed due to commercial sensitivity.